Sign in
Taking people in United StatesPhase 2

Lower-dose chemotherapy before CAR T-cell therapy in people with kidney problems

Tests adjusted chemotherapy before CAR T-cell therapy in adults with B-cell cancers.

Key facts

Who runs it
Northside Hospital, Inc.
Where
Atlanta, United StatesSee the site
Trial code
Registry title
CAR T-cell Therapy in Patients With Renal Dysfunction
Status
Recruiting
Phase
Phase 2
People taking part
20 people, planned
Started
18 Nov 2024
Expected to end
31 Aug 2027
Type of study
Interventional, 3 groups
Treatments tested
  • Fludarabine
  • Cyclophosphamide
Record updated
14 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with multiple myeloma, leukemia or lymphoma who will get CAR-T therapy and have reduced kidney function.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Multiple myeloma, leukemia or lymphoma, with kidney function of 60 mL/min/1.73m2 or lower.
Earlier treatment
People must be getting lymphodepleting chemotherapy before commercial CAR-T treatment. Those on therapeutic-dose steroids (more than 20mg/day prednisone or equivalent) within 72 hours of CAR-T cannot join.

Main reasons for not taking part

  • Relative CNS disorders
  • Active uncontrolled infection or another illness that could interfere with the study
  • Therapeutic-dose systemic steroids (more than 20mg/day prednisone or equivalent) within 72 hours of CAR-T
  • Bone marrow function not adequate for lymphodepleting chemotherapy
  • ECOG score above 2

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Receiving lymphodepleting chemotherapy prior to commercial CAR-T administration for multiple myeloma, leukemia, or lymphoma
  • Adequate bone marrow function to receive lymphodepleting chemotherapy
  • Renal function </= 60mL/min/1.73m2
  • ECOG 0-2

Who cannot take part

  • Active uncontrolled infection or any other concurrent disease or medical condition that was deemed to interfere with the conduct of the study as judged by the investigator
  • Use of therapeutic dose systemic corticosteroids (defined as >20mg/day prednisone or equivalent) within 72 hours of CAR-T administration
  • Relative CNS disorders

Where in United States

  • Caitlin GuzowskiAtlanta, United StatesContact: Caitlin Guzowski, MBA, MHATaking people

About the trial

What the trial wants to find out

This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.

The 3 groups in the trial

  • Moderate Renal DysfunctionTreatment being tested

    Moderate renal dysfunction will receive a 20% dose reduction of fludarabine and no dose reduction for cyclophosphamide.

    Treatment: Fludarabine and Cyclophosphamide

  • Severe Renal DysfunctionTreatment being tested

    Several renal dysfunction will receive a 40% dose reduction of fludarabine and no dose reduction for cyclophosphamide.

    Treatment: Fludarabine and Cyclophosphamide

  • Dialysis ParticipantsTreatment being tested

    Participants on dialysis will receive a 50% dose reduction of fludarabine and a 25% dose reduction of cyclophosphamide.

    Treatment: Fludarabine and Cyclophosphamide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Lymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy in Patients With Moderate-Severe Renal Dysfunction
Plain-language title
Lower-dose chemotherapy before CAR T-cell therapy in people with kidney problemsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
14 October 2026